Thus, IDH mutated and wildtype gliomas appear as two different kinds of tumors not only from a neuropathological point of view due to different pathways at development, but also in the clinical practice predicting both survival and performance–providing a perfect example of basic knowledge translation and collaboration between preclinical and applied medical branches. The gene discussed is IDH1; the disease is glioma.